Article

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing

2025-04-08

Abstract excerpt

DNA methyltransferase 1 inhibitor (DNMT1i) therapy is a promising option for increasing immune response as part of combination cancer therapy. High–grade serous ovarian carcinoma (HGSOC) is a highly aggressive cancer with poor survival outcomes, where DNMT1i therapy is being increasingly explored. HGSOC with epigenetically silenced BRCA1 has been shown to respond to PARP inhibitor (PARPi) treatment – a core target...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b67dac91-922e-58a2-99b2-467ac5801926
DOI: 10.1101/2025.04.07.647418

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingDOI 10.1101/2025.04.07.647418Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editingSemantic proximity Read

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaSemantic proximity Read

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read

Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancerSemantic proximity Read

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read